• Immunohistochemical analysis of paraffin-embedded human tonsil. 1, Antibody was diluted at 1:200 (4°C overnight). 2, Tris-EDTA, pH9.0 was used for antigen retrieval. 3, Secondary antibody was diluted at 1:200 (room temperature, 30min).

Anti-MXRA5 antibody (STJ192207)

SKU:
STJ192207

Current Stock:
Host: Rabbit
Applications: IHC/IF
Reactivity: Human/Rat/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Matrix-remodeling-associated protein 5 is suitable for use in Immunohistochemistry and Immunofluorescence research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: IHC-P 1:50-300
IF 1:50-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: MXRA5
Gene ID: 25878
Uniprot ID: MXRA5_HUMAN
Specificity: MXRA5 Polyclonal Antibody detects endogenous levels of protein.
Immunogen: Synthesized peptide derived from part of the human protein
Function In kidney, has anti-inflammatory and anti-fibrotic properties by limiting the induction of chemokines, fibronectin and collagen expression in response to TGB1 and pro-inflammatory stimuli.
Protein Name Matrix-Remodeling-Associated Protein 5
Adhesion Protein With Leucine-Rich Repeats And Immunoglobulin Domains Related To Perlecan
Adlican
Cellular Localisation Secreted
Alternative Antibody Names Anti-Matrix-Remodeling-Associated Protein 5 antibody
Anti-Adhesion Protein With Leucine-Rich Repeats And Immunoglobulin Domains Related To Perlecan antibody
Anti-Adlican antibody
Anti-MXRA5 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance